Latest news with #OPRX
Yahoo
3 days ago
- Business
- Yahoo
Here's Why OptimizeRx Corp. (OPRX) is a Great Momentum Stock to Buy
Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades. While many investors like to look for momentum in stocks, this can be very tough to define. There is a lot of debate surrounding which metrics are the best to focus on and which are poor quality indicators of future performance. The Zacks Momentum Style Score, part of the Zacks Style Scores, helps address this issue for us. Below, we take a look at OptimizeRx Corp. (OPRX), a company that currently holds a Momentum Style Score of B. We also talk about price change and earnings estimate revisions, two of the main aspects of the Momentum Style Score. It's also important to note that Style Scores work as a complement to the Zacks Rank, our stock rating system that has an impressive track record of outperformance. OptimizeRx Corp. Currently has a Zacks Rank of #1 (Strong Buy). Our research shows that stocks rated Zacks Rank #1 (Strong Buy) and #2 (Buy) and Style Scores of A or B outperform the market over the following one-month period. You can see the current list of Zacks #1 Rank Stocks here >>> In order to see if OPRX is a promising momentum pick, let's examine some Momentum Style elements to see if this company holds up. A good momentum benchmark for a stock is to look at its short-term price activity, as this can reflect both current interest and if buyers or sellers currently have the upper hand. It is also useful to compare a security to its industry, as this can help investors pinpoint the top companies in a particular area. For OPRX, shares are up 4.21% over the past week while the Zacks Computer - Software industry is up 1.28% over the same time period. Shares are looking quite well from a longer time frame too, as the monthly price change of 43.09% compares favorably with the industry's 1.82% performance as well. While any stock can see its price increase, it takes a real winner to consistently beat the market. That is why looking at longer term price metrics -- such as performance over the past three months or year -- can be useful as well. Over the past quarter, shares of OptimizeRx Corp. Have risen 98.32%, and are up 25.6% in the last year. In comparison, the S&P 500 has only moved 1.99% and 12.34%, respectively. Investors should also pay attention to OPRX's average 20-day trading volume. Volume is a useful item in many ways, and the 20-day average establishes a good price-to-volume baseline; a rising stock with above average volume is generally a bullish sign, whereas a declining stock on above average volume is typically bearish. OPRX is currently averaging 396,163 shares for the last 20 days. The Zacks Momentum Style Score also takes into account trends in estimate revisions, in addition to price changes. Please note that estimate revision trends remain at the core of Zacks Rank as well. A nice path here can help show promise, and we have recently been seeing that with OPRX. Over the past two months, 4 earnings estimates moved higher compared to none lower for the full year. These revisions helped boost OPRX's consensus estimate, increasing from $0.40 to $0.51 in the past 60 days. Looking at the next fiscal year, 3 estimates have moved upwards while there have been no downward revisions in the same time period. Taking into account all of these elements, it should come as no surprise that OPRX is a #1 (Strong Buy) stock with a Momentum Score of B. If you've been searching for a fresh pick that's set to rise in the near-term, make sure to keep OptimizeRx Corp. On your short list. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report OptimizeRx Corp. (OPRX) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
13-05-2025
- Business
- Yahoo
OptimizeRx Corp (OPRX) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Shifts
Revenue: $21.9 million, an increase of 11% year over year. Gross Margin: 60.9%, down from 62% in the previous year. Net Loss: $2.2 million or $0.12 per share, compared to a net loss of $6.9 million or $0.38 per share in the previous year. Non-GAAP Net Loss: $1.5 million or $0.08 per share, compared to $2 million or $0.11 per share in the previous year. Adjusted EBITDA: $1.5 million, compared to a $0.3 million loss in the previous year. Operating Cash Flow: $3.9 million for the first quarter. Cash Balance: $16.6 million at the end of the quarter. Debt Balance: $33.8 million, with $6.2 million of principal paid off in the first quarter. Committed Contracted Revenue: Exceeded $70 million, a greater-than-25% improvement year over year. Average Revenue per Top 20 Pharmaceutical Manufacturer: Approximately $3 million. Net Revenue Retention Rate: 114%. Revenue per FTE: $710,000, up from $641,000 in the previous year. Warning! GuruFocus has detected 2 Warning Sign with OPRX. Release Date: May 12, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. OptimizeRx Corp (NASDAQ:OPRX) reported Q1 2025 revenues of $21.9 million, an 11% increase year over year, surpassing both consensus estimates and internal expectations. The company improved its adjusted EBITDA to $1.5 million, a significant increase from a loss of $0.3 million in Q1 2024. Contracted revenue increased by more than 20% year over year, providing strong visibility and positioning for the remainder of the year. The company raised its full-year revenue guidance to between $101 million and $106 million, with adjusted EBITDA expected between $13 million and $15 million. Early momentum in transitioning to a subscription-based model, with over 5% of projected annual revenue already converted to subscription contracts for 2025. Gross margin decreased from 62% in Q1 2024 to 60.9% in Q1 2025, primarily due to product and channel partner mix. The company reported a net loss of $2.2 million for Q1 2025, although this was an improvement from a $6.9 million loss in Q1 2024. Despite improvements, the company still faces challenges in achieving multi-year subscription contracts due to the annual budgeting nature of the pharma industry. The transition to a subscription-based model may impact revenue recognition, spreading revenue over a 12-month period. The company has a debt balance of $33.8 million, although it has paid off $6.2 million of principal in Q1 2025. Q: With the current market noise, including tariffs and price negotiations, have you seen any hesitation from your customers? A: Stephen Silvestro, President and Chief Commercial Officer, stated that they have not seen any pull-back from clients. They are receiving real-time updates and have observed clients leaning in more to drive market efforts, particularly leveraging digital channels. Q: How does the transition to a subscription-based revenue model impact revenue recognition and margins? A: Edward Stelmakh, Chief Financial Officer, explained that subscription revenue is spread over a 12-month period, which is accretive due to the revenue share perspective. The cost of sales for subscription revenue is relatively low, benefiting margins. Q: Can you provide clarity on the gross margin profile, given the increase in direct-to-consumer managed services? A: Edward Stelmakh noted that while some solutions have lower margins, the company is diversified enough to maintain a stable gross margin profile. They aim to increase margins above the low 60% range, but currently, they are comfortable with the existing range. Q: What is the visibility on committed revenue for the year, and how does it compare to last year? A: Stephen Silvestro confirmed that committed revenue is north of 80%, showing a 25% improvement over the previous year. This increased visibility gives them confidence in their guidance. Q: Regarding the pipeline, how are win rates and average deal sizes evolving? A: Stephen Silvestro mentioned that the pipeline continues to grow steadily, with improved conversion rates, particularly in data and subscription components. However, they did not disclose specific average deal sizes for competitive reasons. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
Yahoo
30-03-2025
- Business
- Yahoo
OptimizeRx Corporation (NASDAQ:OPRX) is favoured by institutional owners who hold 59% of the company
Institutions' substantial holdings in OptimizeRx implies that they have significant influence over the company's share price A total of 11 investors have a majority stake in the company with 52% ownership Insiders have bought recently This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. A look at the shareholders of OptimizeRx Corporation (NASDAQ:OPRX) can tell us which group is most powerful. And the group that holds the biggest piece of the pie are institutions with 59% ownership. Put another way, the group faces the maximum upside potential (or downside risk). Since institutional have access to huge amounts of capital, their market moves tend to receive a lot of scrutiny by retail or individual investors. Hence, having a considerable amount of institutional money invested in a company is often regarded as a desirable trait. In the chart below, we zoom in on the different ownership groups of OptimizeRx. See our latest analysis for OptimizeRx Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices. As you can see, institutional investors have a fair amount of stake in OptimizeRx. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of OptimizeRx, (below). Of course, keep in mind that there are other factors to consider, too. Investors should note that institutions actually own more than half the company, so they can collectively wield significant power. It would appear that 8.2% of OptimizeRx shares are controlled by hedge funds. That's interesting, because hedge funds can be quite active and activist. Many look for medium term catalysts that will drive the share price higher. Looking at our data, we can see that the largest shareholder is Whetstone Capital Advisors, LLC with 8.2% of shares outstanding. Meanwhile, the second and third largest shareholders, hold 7.5% and 7.2%, of the shares outstanding, respectively. A closer look at our ownership figures suggests that the top 11 shareholders have a combined ownership of 52% implying that no single shareholder has a majority. Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future. The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it. Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances. Our information suggests that insiders maintain a significant holding in OptimizeRx Corporation. Insiders have a US$23m stake in this US$160m business. We would say this shows alignment with shareholders, but it is worth noting that the company is still quite small; some insiders may have founded the business. You can click here to see if those insiders have been buying or selling. With a 18% ownership, the general public, mostly comprising of individual investors, have some degree of sway over OptimizeRx. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run. It's always worth thinking about the different groups who own shares in a company. But to understand OptimizeRx better, we need to consider many other factors. To that end, you should learn about the 2 warning signs we've spotted with OptimizeRx (including 1 which is a bit unpleasant) . But ultimately it is the future, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
11-03-2025
- Business
- Yahoo
OptimizeRx Corporation Confirms Receipt of Notice of Director Nominations
No Stockholder Action Required at this Time WALTHAM, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the 'Company') (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today confirmed that it has received a purported notice of nominations from a stockholder, Whetstone Capital Advisors, LLC, regarding its intention to nominate two candidates for election to the OptimizeRx Board of Directors at the Company's 2025 Annual Meeting of Stockholders. The OptimizeRx Board of Directors will make its formal recommendation regarding director nominations in the Company's definitive proxy statement which will be filed with the Securities and Exchange Commission and mailed to stockholders eligible to vote at the Company's 2025 Annual Meeting of Stockholders, which has not yet been scheduled. About OptimizeRx OptimizeRx is a leading healthcare technology company that's redefining how life science brands connect with patients and healthcare providers. Our platform combines innovative AI-driven tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT) to deliver timely, relevant, and hyper-local engagement. By bridging the gap between HCP and DTC strategies, we empower brands to create synchronized marketing solutions that drive faster treatment decisions and improved patient outcomes. Our commitment to privacy-safe, patient-centric technology ensures that every interaction is designed to make a meaningful impact, delivering life-changing therapies to the right patients at the right time. Headquartered in Waltham, Massachusetts, OptimizeRx partners with some of the world's leading pharmaceutical and life sciences companies to transform the healthcare landscape and create a healthier future for all. Important Cautions Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as 'anticipates', 'believes', 'estimates', 'expects', 'forecasts', 'intends', 'plans', 'projects', 'targets', 'designed', 'could', 'may', 'should', 'will' or other similar words and expressions are intended to identify these forward-looking statements. All statements in this press release that reflect the Company's expectations, assumptions, projections, beliefs or opinions about the future, other than statements of historical fact, are forward-looking statements. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon the Company's current expectations and involve assumptions regarding the Company's business, the economy, and other future conditions that may never materialize or may prove to be incorrect. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties including, but not limited to, the effect of government regulation, seasonal trends, dependence on a concentrated group of customers, cybersecurity incidents that could disrupt operations, the ability to keep pace with growing and evolving technology, the ability to maintain contracts with electronic prescription platforms and electronic health records networks, competition, and other factors discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2023, and in other filings the Company has made and may make with the SEC in the future. One should not place undue reliance on these forward-looking statements, which speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law. Important Additional Information And Where To Find It OptimIzeRx Corporation (the 'Company') plans to file proxy materials with the U.S. Securities and Exchange Commission (the 'SEC') in connection with the solicitation of proxies for the Company's 2025 annual meeting of stockholders (the '2025 Annual Meeting'). Prior to the 2025 Annual Meeting, the Company will file a definitive proxy statement (the 'Proxy Statement') together with a WHITE proxy card. STOCKHOLDERS ARE URGED TO READ THE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS THAT THE COMPANY WILL FILE WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Stockholders will be able to obtain, free of charge, copies of the Proxy Statement, any amendments or supplements thereto and any other documents (including the WHITE proxy card) when filed by the Company with the SEC at the SEC's website ( or at the Company's website at or by contacting Andy D'Silva, SVP - Finance, by email at adsilva@ or by mail at OptimizeRx Corporation, 260 Charles Street, Suite 302, Waltham, MA 02453. Certain Information Regarding Participants The Company, its directors, certain of its executive officers, and other employees may be deemed to be 'participants' (as defined in Section 14(a) of the Securities Exchange Act of 1934, as amended) in the solicitation of proxies from stockholders in connection with the 2025 Annual Meeting. Additional information regarding the identity of these participants and their direct or indirect interests, by security holdings or otherwise, will be set forth in the Proxy Statement and other materials to be filed with the SEC in connection with the 2025 Annual Meeting. Information relating to the foregoing can also be found in the Company's definitive proxy statement for its 2024 annual meeting of stockholders, filed with the SEC on April 29, 2024. To the extent holdings of such participants in the Company's securities have changed since the amounts described in the 2024 proxy statement, such changes have been reflected in the following Statements of Change in Beneficial Ownership on Form 4 filed with the SEC with respect to the Company: Form 4, filed by Stephen L. Silvestro on March 4, 2025; Form 4, filed by Stephen L. Silvestro on February 20, 2025; Form 4, filed by Edward Stelmakh on February 20, 2025; Form 4, filed by Cathy Klema on February 4, 2025; Form 4/A, filed by Edward Stelmakh on December 27, 2024; Form 4, filed by Stephen L. Silvestro on December 27, 2024; Form 4, filed by Edward Stelmakh on December 27, 2024; Form 4, filed by Edward Stelmakh on December 20, 2024; Form 4, filed by Stephen L. Silvestro on December 20, 2024; Form 4, filed by Edward Stelmakh on October 15, 2024; Form 4, filed by Stephen L. Silvestro on October 7, 2024; Form 4, filed by Edward Stelmakh on October 7, 2024; Form 4, filed by Gregory D. Wasson on June 11, 2024; Form 4, filed by Cathy Klema on June 11, 2024; Form 4, filed by Ellen O'Connor Vos on June 11, 2024; Form 4, filed by James Paul Lang on June 11, 2024; Form 4, filed by Patrick Spangler on June 11, 2024; Form 4/A, filed by Stephen L. Silvestro on May 6, 2024; Form 4, filed by Stephen L. Silvestro on May 6, 2024; and Form 4/A, filed by Stephen L. Silvestro on May 6, 2024. These filings can be found at the SEC's website at More detailed and updated information regarding the identity of participants in the solicitation, and their direct or indirect interests (by security holdings or otherwise), will be set forth in the Proxy Statement and other materials to be filed with the SEC. These documents can be obtained free of charge from the sources indicated above. OptimizeRx Contact Andy D'Silva, SVP Corporate Finance adsilva@ Investor Relations ContactSandya von der WeidLifeSci Advisors, LLCsvonderweid@ in to access your portfolio
Associated Press
10-03-2025
- Business
- Associated Press
OptimizeRx Corporation Appoints Stephen Silvestro as Chief Executive Officer
WALTHAM, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the 'Company') (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced it has appointed Steve Silvestro as the Company's new Chief Executive Officer, effective March 10, 2025. Mr. Silvestro brings to OptimizeRx more than 20 years of experience in building and managing health technology and services companies, and has served as an executive at OptimizeRx since joining the Company in 2019. His career includes strategic development, sales leadership, technology and product innovation, and M&A within a variety of leadership roles. 'The Board of Directors completed a rigorous search and selection process for a new CEO that was conducted by the Company's independent Directors with the assistance of a leading executive search firm and is very pleased to announce that it was the unanimous decision of the independent Directors to appoint Steve Silvestro as the next OptimizeRx CEO,' said Lynn Vos, Chairperson of OptimizeRx's Board of Directors. 'Since starting at OptimizeRx six years ago as the Chief Commercial Officer, and more recently serving as President and interim CEO, Steve has been instrumental in growing the Company's brand relevance within the life sciences industry and transforming the Company from an early stage, single solution in the digital marketing space to an industry mainstay with omnichannel capabilities. At this pivotal time in OptimizeRx's history, we are confident that Steve is the right transformative leader to drive OptimizeRx into its next phase of profitable revenue growth and shareholder value creation.' 'I am honored to have the Board's trust and to have the opportunity to lead the next phase of OptimizeRx's growth and transformation. We will continue to differentiate ourselves within the market through our technology and by developing more meaningful strategic partnerships with our customers. Now more than ever, we will be laser-focused on operational excellence while ensuring we delight our customers and forge stronger relationships with valued business partners,' added Steve Silvestro. 'Since the time I was asked to take the helm in December, we have completed an extensive strategic review of the Company's business processes, operations, and opportunities for shareholder value creation. I look forward to collaborating with our Board, team members, strategic partners, and customers as we continue the Company's growth, focusing very closely on customer centricity and delight, continuing to expand our value proposition with pharma, increasing our re-occurring revenue model while driving to become a Rule of 40 company, and unlocking new opportunities for profitable revenue growth and shareholder value creation.' Mr. Silvestro's Bio Mr. Silvestro was appointed the Chief Executive Officer in March 2025. He joined the Company as Chief Commercial Officer in April 2019, and has since served as President and, most recently, as the Company's interim CEO. Prior to joining the Company, Mr. Silvestro held leadership positions at various companies including CCH® Tagetik, a Wolters Kluwer company that provides corporate performance management software solutions for planning, consolidation and reporting, Prognos Health, Inc., a healthcare data and analytics company, Decision Resources Group, a multi-national corporation that provides high value global data solutions, analytics and consulting services to pharmaceutical, biotech, medical device, healthcare provider and payer companies. Mr. Silvestro received his Master of Liberal Arts in Business Management from Harvard University and his Bachelor of Arts in Italian and Business Management from Brigham Young University. About OptimizeRx OptimizeRx is a leading healthcare technology company that's redefining how life science brands connect with patients and healthcare providers. Our platform combines innovative AI-driven tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT) to deliver timely, relevant, and hyper-local engagement. By bridging the gap between HCP and DTC strategies, we empower brands to create synchronized marketing solutions that drive faster treatment decisions and improved patient outcomes. Our commitment to privacy-safe, patient-centric technology ensures that every interaction is designed to make a meaningful impact, delivering life-changing therapies to the right patients at the right time. Headquartered in Waltham, Massachusetts, OptimizeRx partners with some of the world's leading pharmaceutical and life sciences companies to transform the healthcare landscape and create a healthier future for all. Important Cautions Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as 'anticipates', 'believes', 'estimates', 'expects', 'forecasts', 'intends', 'plans', 'projects', 'targets', 'designed', 'could', 'may', 'should', 'will' or other similar words and expressions are intended to identify these forward-looking statements. All statements in this press release that reflect the Company's expectations, assumptions, projections, beliefs or opinions about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements relating to the future contributions of Mr. Silvestro to the Company, the Company's growth and transformation, plans for profitable revenue growth, plans for creating, enhancing and unlocking shareholder value, plans for differentiating the Company through its technology, plans for developing more meaningful strategic partnerships with the Company's customers, plans for expanding the Company's value proposition with pharma, plans for increasing the Company's re-occurring revenue while driving to become a Rule of 40 company and unlocking new opportunities for profitable revenue growth, plans for expanding relationships with customers and strategic partners, plans for forging stronger relationships with valued business partners, other business plans and operating and financial performance objectives, and other statements relating to future performance, plans, and expectations. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon the Company's current expectations and involve assumptions regarding the Company's business, the economy, and other future conditions that may never materialize or may prove to be incorrect. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties including, but not limited to, the effect of government regulation, seasonal trends, dependence on a concentrated group of customers, cybersecurity incidents that could disrupt operations, the ability to keep pace with growing and evolving technology, the ability to maintain contracts with electronic prescription platforms and electronic health records networks, competition, and other factors discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2023, and in other filings the Company has made and may make with the SEC in the future. One should not place undue reliance on these forward-looking statements, which speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law. Sandya von der Weid
